AtriCure
ATRC
53.31
-0.37
-0.69%
AtriCure
US · ATRC
#2543 by market cap
Listed 1970
53.31
-0.37
-0.69%
Live - 5344 symbols - heartbeat 59s ago
· 2026-10-07 19:54
After-hours
53.31
0.00%
- Market cap
- 2.71B
- P/E (TTM)i
- 253.86
- P/Bi
- 5.25
- EPSi
- -0.24
- Div yieldi
- 0.00%
- 52W posi
- 77%
Reader sentiment
Are you bullish or bearish on ATRC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 105.53% -0.01pp
- Institutions
- 307
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund88.01%
Hedge Fund11.56%
Individual/Insider4.01%
Public Company2.70%
Private Company1.01%
Sovereign Wealth Fund0.74%
Insurance Company0.73%
Government Pension Fund0.72%
Top holders as of 2026-06-30
BlackRock
8.80% · 4.47M sh
Wellington Management Group
6.87% · 3.50M sh
Vanguard Portfolio Management, LLC
6.15% · 3.13M sh
Hood River Capital Management LLC
5.71% · 2.91M sh
AllianceBernstein
5.44% · 2.77M sh
Vanguard Capital Management, LLC
5.01% · 2.55M sh
Macquarie Investment Management Business Trust
3.41% · 1.73M sh
Goldman Sachs Asset Management, L.P.
2.91% · 1.48M sh
State Street Global Advisors
2.73% · 1.39M sh
Marshall Wace LLP
2.62% · 1.33M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Michael Carrel | Chief Executive Officer | 1.56% |
| Douglas Seith | Chief Operating Officer | 0.45% |
| Angela Wirick | Chief Financial Officer | 0.40% |
| Salvatore Privitera | Chief Technology Officer | 0.28% |
| Robert White | Independent Director | 0.25% |
| Justin Noznesky | Chief Marketing & Strategy Officer | 0.20% |
| Karl Dahlquist | Chief Legal Officer | 0.17% |
| Vinayak Doraiswamy | Chief Scientific Officer | 0.17% |
| B. Johnson | Independent Chairperson | 0.11% |
| Deborah Yount | Chief Human Resources Officer | 0.09% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-22 | Salvatore Privitera | Chief Technology Officer | Automatic Disposition | -4,519 | $60.00 |
| 2026-09-10 | Regina Groves | Independent Director | Open Market Disposition | -5,313 | $54.22 |
| 2026-09-09 | Regina Groves | Independent Director | Intent to Sell (Form 144) | -5,313 | $53.66 |
| 2026-09-07 | Salvatore Privitera | Chief Technology Officer | Automatic Disposition | -3,657 | $55.00 |
| 2026-09-01 | Salvatore Privitera | Chief Technology Officer | Automatic Disposition | -7,763 | $52.50 |
| 2026-08-23 | Karl Dahlquist | Chief Legal Officer | Open Market Disposition | -9,370 | $48.89 |
| 2026-08-04 | Karen Prange | Independent Director | Open Market Disposition | -3,564 | $38.80 |
| 2026-08-04 | Maggie Yuen | Independent Director | Open Market Disposition | -3,500 | $38.42 |
| 2026-07-29 | Michael Carrel | Chief Executive Officer | Other Disposition | -4,700 | -- |
| 2026-07-28 | Justin Noznesky | Chief Marketing & Strategy Officer | Open Market Disposition | -6,182 | $38.80 |
| 2026-07-27 | Sven Wehrwein | Independent Director | Derivative Exercise and Sale | -25,000 | $19.95–37.84 |
| 2026-07-27 | Vinayak Doraiswamy | Chief Scientific Officer | Open Market Disposition | -6,000 | $38.88 |
| 2026-06-29 | Michael Carrel | Chief Executive Officer | Other Acquisition | +636 | $23.78 |
| 2026-06-29 | Salvatore Privitera | Chief Technology Officer | Other Acquisition | +636 | $23.78 |
| 2026-06-29 | Douglas Seith | Chief Operating Officer | Other Acquisition | +527 | $23.78 |
| 2026-06-29 | Karl Dahlquist | Chief Legal Officer | Other Acquisition | +636 | $23.78 |
| 2026-06-29 | Vinayak Doraiswamy | Chief Scientific Officer | Other Acquisition | +636 | $23.78 |
| 2026-05-19 | Karen Prange | Independent Director | Open Market Disposition | -3,000 | $28.65 |
| 2026-05-17 | Sven Wehrwein | Independent Director | Other Acquisition | +6,144 | -- |
| 2026-05-17 | B. Johnson | Independent Chairperson | Other Acquisition | +6,144 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.